Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Corbus Pharmaceuticals Holdings, Inc.
13G
CRBP · 21833P301
|
9.9% |
9/30/2026
Event 9/23/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
BetterLife Pharma Inc.
13G
BETRF · 08772P202
|
9.0% |
9/22/2026
Event 9/15/2026
|
|||
| RA Capital Management, L.P. | 9.0% | ||||
| Peter Kolchinsky | 9.0% | ||||
| Rajeev Shah | 9.0% | ||||
| RA Capital Healthcare Fund, L.P. | 9.0% | ||||
|
Sionna Therapeutics, Inc.
13D/A
Amendment 2
SION · 829401108
|
14.3% |
9/21/2026
Event 9/17/2026
|
|||
| RA Capital Management, L.P. | 14.3% | ||||
| Peter Kolchinsky | 14.3% | ||||
| Rajeev Shah | 14.3% | ||||
| RA Capital Healthcare Fund, L.P. | 7.6% | ||||
| RA Capital Nexus Fund III, L.P. | 4.9% | ||||
|
Tyra Biosciences, Inc.
13D/A
Amendment 7
TYRA · 90240B106
|
19.9% |
9/17/2026
Event 9/15/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 17.2% | ||||
|
JATT III Acquisition Corp
13G
G5080G109
|
5.1% |
9/3/2026
Event 8/27/2026
|
|||
| RA Capital Management, L.P. | 5.1% | ||||
| Peter Kolchinsky | 5.1% | ||||
| Rajeev Shah | 5.1% | ||||
| RA Capital Healthcare Fund, L.P. | 5.1% | ||||
|
Latigo Biotherapeutics, Inc.
13G
LTGO · 517954103
|
8.4% |
8/17/2026
Event 8/10/2026
|
|||
| RA Capital Management, L.P. | 8.4% | ||||
| Peter Kolchinsky | 8.4% | ||||
| Rajeev Shah | 8.4% | ||||
| RA Capital Healthcare Fund, L.P. | 8.4% | ||||
|
GH Research PLC
13G/A
Amendment 8
GHRS · G3855L106
|
7.1% |
8/14/2026
Event 8/12/2026
|
|||
| RA Capital Management, L.P. | 7.1% | ||||
| Peter Kolchinsky | 7.1% | ||||
| Rajeev Shah | 7.1% | ||||
| RA Capital Healthcare Fund, L.P. | 6.9% | ||||
|
Septerna, Inc.
13D/A
Amendment 1
SEPN · 81734D104
|
11.8% |
8/14/2026
Event 8/12/2026
|
|||
| RA Capital Management, L.P. | 11.8% | ||||
| Peter Kolchinsky | 11.8% | ||||
| Rajeev Shah | 11.8% | ||||
| RA Capital Healthcare Fund, L.P. | 10.2% | ||||
|
Taysha Gene Therapies, Inc.
13G/A
Amendment 5
TSHA · 877619106
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Rani Therapeutics Holdings, Inc.
13G/A
Amendment 1
RANI · 753018100
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Ovid Therapeutics Inc.
13G/A
Amendment 1
OVID · 690469101
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
Amendment 1
KPTI · 48576U205
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Geron Corporation
13G/A
Amendment 6
GERN · 374163103
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Fulcrum Therapeutics, Inc.
13G/A
Amendment 7
FULC · 359616109
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Edgewise Therapeutics, Inc.
13G/A
Amendment 2
EWTX · 28036F105
|
7.8% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 7.8% | ||||
| Peter Kolchinsky | 7.8% | ||||
| Rajeev Shah | 7.8% | ||||
| RA Capital Healthcare Fund, L.P. | 7.8% | ||||
|
CervoMed Inc.
13G/A
Amendment 4
CRVO · 15713L109
|
8.6% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 8.6% | ||||
| Peter Kolchinsky | 8.6% | ||||
| Rajeev Shah | 8.6% | ||||
| RA Capital Healthcare Fund, L.P. | 8.6% | ||||
|
C4 Therapeutics, Inc.
13G/A
Amendment 1
CCCC · 12529R107
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
BioCryst Pharmaceuticals, Inc.
13G/A
Amendment 1
BCRX · 09058V103
|
6.2% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 6.2% | ||||
| Peter Kolchinsky | 6.2% | ||||
| Rajeev Shah | 6.2% | ||||
| RA Capital Healthcare Fund, L.P. | 6.2% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 5
AVTX · 05338F306
|
6.3% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 6.3% | ||||
| Peter Kolchinsky | 6.3% | ||||
| Rajeev Shah | 6.3% | ||||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||||
|
Atrium Therapeutics, Inc.
13G/A
Amendment 1
RNA · 04965N104
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Adicet Bio, Inc.
13G/A
Amendment 4
ACET · 007002207
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Aclaris Therapeutics, Inc.
13G/A
Amendment 1
ACRS · 00461U105
|
9.1% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.1% | ||||
| Peter Kolchinsky | 9.1% | ||||
| Rajeev Shah | 9.1% | ||||
| RA Capital Healthcare Fund, L.P. | 9.1% | ||||
|
TCGX Acquisition Corp.
13G
TCGX · G8708J109
|
5.5% |
8/13/2026
Event 8/6/2026
|
|||
| RA Capital Management, L.P. | 5.5% | ||||
| Peter Kolchinsky | 5.5% | ||||
| Rajeev Shah | 5.5% | ||||
| RA Capital Healthcare Fund, L.P. | 5.5% | ||||
|
Wave Life Sciences, Inc.
13D/A
Amendment 11
WVE · 94352A104
|
16.8% |
8/11/2026
Event 8/7/2026
|
|||
| RA Capital Management, L.P. | 16.8% | ||||
| Peter Kolchinsky | 16.8% | ||||
| Rajeev Shah | 16.8% | ||||
| RA Capital Healthcare Fund, L.P. | 16.7% | ||||
|
SAB Biotherapeutics, Inc.
13D/A
Amendment 3
SABS · 78397T202
|
9.9% |
8/10/2026
Event 8/6/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Obsidian Therapeutics, Inc.
13G
OBX · 67448A106
|
9.7% |
8/10/2026
Event 8/3/2026
|
|||
| RA Capital Management, L.P. | 9.7% | ||||
| Peter Kolchinsky | 9.7% | ||||
| Rajeev Shah | 9.7% | ||||
| RA Capital Healthcare Fund, L.P. | 8.0% | ||||
|
Inovio Pharmaceuticals, Inc.
13G
INO · 45773H409
|
9.9% |
8/7/2026
Event 7/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
DBV Technologies S.A.
13G
DBVT · 23306J309
|
5.8% |
8/6/2026
Event 7/30/2026
|
|||
| RA Capital Management, L.P. | 5.8% | ||||
| Peter Kolchinsky | 5.8% | ||||
| Rajeev Shah | 5.8% | ||||
| RA Capital Healthcare Fund, L.P. | 5.8% | ||||
|
Scribe Therapeutics Inc.
13G
SCTX · 811033109
|
9.6% |
8/3/2026
Event 7/27/2026
|
|||
| RA Capital Management, L.P. | 9.6% | ||||
| Peter Kolchinsky | 9.6% | ||||
| Rajeev Shah | 9.6% | ||||
| RA Capital Healthcare Fund, L.P. | 9.1% | ||||
|
Capricor Therapeutics, Inc.
13G
CAPR · 14070B309
|
5.2% |
8/3/2026
Event 7/27/2026
|
|||
| RA Capital Management, L.P. | 5.2% | ||||
| Peter Kolchinsky | 5.2% | ||||
| Rajeev Shah | 5.2% | ||||
| RA Capital Healthcare Fund, L.P. | 5.2% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 1
IKT · 45719W205
|
9.9% |
7/31/2026
Event 7/29/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Artiva Biotherapeutics, Inc.
13D/A
Amendment 4
ARTV · 04317A107
|
37.9% |
7/23/2026
Event 7/22/2026
|
|||
| RA Capital Management, L.P. | 37.9% | ||||
| Peter Kolchinsky | 37.9% | ||||
| Rajeev Shah | 37.9% | ||||
| RA Capital Healthcare Fund, L.P. | 35.5% | ||||
|
Freenome, Inc.
13D/A
Amendment 1
FRNM · 35661P100
|
14.3% |
7/22/2026
Event 7/20/2026
|
|||
| RA Capital Management, L.P. | 14.3% | ||||
| Peter Kolchinsky | 14.3% | ||||
| Rajeev Shah | 14.3% | ||||
| RA Capital Healthcare Fund, L.P. | 11.4% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 18
VOR · 929033207
|
19.9% |
7/21/2026
Event 7/16/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Agenus Inc.
13G
AGEN · 00847G804
|
9.9% |
7/20/2026
Event 7/13/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Inhibikase Therapeutics, Inc.
13G
IKT · 45719W205
|
15.9% |
7/17/2026
Event 7/10/2026
|
|||
| RA Capital Management, L.P. | 15.9% | ||||
| Peter Kolchinsky | 15.9% | ||||
| Rajeev Shah | 15.9% | ||||
| RA Capital Healthcare Fund, L.P. | 15.9% | ||||
|
Climb Bio, Inc.
13D/A
Amendment 10
CLYM · 28658R106
|
33.0% |
7/7/2026
Event 7/2/2026
|
|||
| RA Capital Management, L.P. | 33.0% | ||||
| Peter Kolchinsky | 33.0% | ||||
| Rajeev Shah | 33.0% | ||||
| RA Capital Healthcare Fund, L.P. | 24.1% | ||||
| RA Capital Nexus Fund III, L.P. | 6.4% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
Amendment 12
HOWL · 95075A107
|
4.1% |
7/2/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 4.1% | ||||
| Peter Kolchinsky | 4.1% | ||||
| Rajeev Shah | 4.1% | ||||
| RA Capital Healthcare Fund, L.P. | 3.8% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
Amendment 11
HOWL · 95075A107
|
6.0% |
6/26/2026
Event 6/24/2026
|
|||
| RA Capital Management, L.P. | 6.0% | ||||
| Peter Kolchinsky | 6.0% | ||||
| Rajeev Shah | 6.0% | ||||
| RA Capital Healthcare Fund, L.P. | 5.6% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 13
SLDB · 83422E204
|
11.9% |
6/24/2026
Event 6/22/2026
|
|||
| RA Capital Management, L.P. | 11.9% | ||||
| Peter Kolchinsky | 11.9% | ||||
| Rajeev Shah | 11.9% | ||||
| RA Capital Healthcare Fund, L.P. | 11.8% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
Amendment 10
HOWL · 95075A107
|
7.5% |
6/22/2026
Event 6/17/2026
|
|||
| RA Capital Management, L.P. | 7.5% | ||||
| Peter Kolchinsky | 7.5% | ||||
| Rajeev Shah | 7.5% | ||||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||||
|
Parabilis Medicines, Inc.
13D
PBLS · 698955101
|
23.8% |
6/18/2026
Event 6/11/2026
|
|||
| RA Capital Management, L.P. | 23.8% | ||||
| Peter Kolchinsky | 23.8% | ||||
| Rajeev Shah | 23.8% | ||||
| RA Capital Healthcare Fund, L.P. | 21.6% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
Amendment 9
HOWL · 95075A107
|
10.6% |
6/15/2026
Event 6/11/2026
|
|||
| RA Capital Management, L.P. | 10.6% | ||||
| Peter Kolchinsky | 10.6% | ||||
| Rajeev Shah | 10.6% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Artiva Biotherapeutics, Inc.
13D/A
Amendment 3
ARTV · 04317A107
|
36.6% |
6/15/2026
Event 6/11/2026
|
|||
| RA Capital Management, L.P. | 36.6% | ||||
| Peter Kolchinsky | 36.6% | ||||
| Rajeev Shah | 36.6% | ||||
| RA Capital Healthcare Fund, L.P. | 34.2% | ||||
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
9.8% |
6/4/2026
Event 5/28/2026
|
|||
| RA Capital Management, L.P. | 9.8% | ||||
| Peter Kolchinsky | 9.8% | ||||
| Rajeev Shah | 9.8% | ||||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||||
|
Editas Medicine, Inc.
13G
EDIT · 28106W103
|
5.8% |
6/3/2026
Event 5/27/2026
|
|||
| RA Capital Management, L.P. | 5.8% | ||||
| Peter Kolchinsky | 5.8% | ||||
| Rajeev Shah | 5.8% | ||||
| RA Capital Healthcare Fund, L.P. | 5.8% | ||||
|
Sana Biotechnology, Inc.
13G
SANA · 799566104
|
6.3% |
5/21/2026
Event 5/14/2026
|
|||
| RA Capital Management, L.P. | 6.3% | ||||
| Peter Kolchinsky | 6.3% | ||||
| Rajeev Shah | 6.3% | ||||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||||
|
Vaxcyte, Inc.
13G/A
Amendment 7
PCVX · 92243G108
|
8.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 8.9% | ||||
| Peter Kolchinsky | 8.9% | ||||
| Rajeev Shah | 8.9% | ||||
| RA Capital Healthcare Fund, L.P. | 8.7% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 7
UNCY · 90466Y202
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 2
PALI · 696389402
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Invivyd, Inc.
13G/A
Amendment 2
IVVD · 00534A102
|
7.0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 7.0% | ||||
| Peter Kolchinsky | 7.0% | ||||
| Rajeev Shah | 7.0% | ||||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||||
|
Dianthus Therapeutics, Inc.
13G/A
Amendment 5
DNTH · 252828108
|
4.8% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 4.8% | ||||
| Peter Kolchinsky | 4.8% | ||||
| Rajeev Shah | 4.8% | ||||
| RA Capital Healthcare Fund, L.P. | 4.8% | ||||
|
Contineum Therapeutics, Inc.
13G/A
Amendment 2
CTNM · 21217B100
|
4.0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 4.0% | ||||
| Peter Kolchinsky | 4.0% | ||||
| Rajeev Shah | 4.0% | ||||
| RA Capital Healthcare Fund, L.P. | 4.0% | ||||
|
Avidity Biosciences, Inc.
13G/A
Amendment 3
RNAM · 05370A108
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 4
AVTX · 05338F306
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Atrium Therapeutics, Inc.
13G
RNA · 04965N104
|
5.6% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 5.6% | ||||
| Peter Kolchinsky | 5.6% | ||||
| Rajeev Shah | 5.6% | ||||
| RA Capital Healthcare Fund, L.P. | 5.6% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 6
FDMT · 35104E100
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
Amendment 8
HOWL · 95075A107
|
12.6% |
5/14/2026
Event 5/12/2026
|
|||
| RA Capital Management, L.P. | 12.6% | ||||
| Peter Kolchinsky | 12.6% | ||||
| Rajeev Shah | 12.6% | ||||
| RA Capital Healthcare Fund, L.P. | 11.7% | ||||
|
Artiva Biotherapeutics, Inc.
13D/A
Amendment 2
ARTV · 04317A107
|
33.7% |
5/13/2026
Event 5/11/2026
|
|||
| RA Capital Management, L.P. | 33.7% | ||||
| Peter Kolchinsky | 33.7% | ||||
| Rajeev Shah | 33.7% | ||||
| RA Capital Healthcare Fund, L.P. | 31.3% | ||||
|
Hemab Therapeutics Holdings, Inc.
13G
COAG · 423494103
|
16.6% |
5/11/2026
Event 5/4/2026
|
|||
| RA Capital Management, L.P. | 16.6% | ||||
| Peter Kolchinsky | 16.6% | ||||
| Rajeev Shah | 16.6% | ||||
| RA Capital Healthcare Fund, L.P. | 13.6% | ||||
|
Altimmune, Inc.
13G
ALT · 02155H200
|
6.5% |
5/1/2026
Event 4/24/2026
|
|||
| RA Capital Management, L.P. | 6.5% | ||||
| Peter Kolchinsky | 6.5% | ||||
| Rajeev Shah | 6.5% | ||||
| RA Capital Healthcare Fund, L.P. | 6.5% | ||||
|
Climb Bio, Inc.
13D/A
Amendment 9
CLYM · 28658R106
|
33.0% |
4/29/2026
Event 4/27/2026
|
|||
| RA Capital Management, L.P. | 33.0% | ||||
| Peter Kolchinsky | 33.0% | ||||
| Rajeev Shah | 33.0% | ||||
| RA Capital Healthcare Fund, L.P. | 25.0% | ||||
| RA Capital Nexus Fund III, L.P. | 9.3% | ||||
| Sera Medicines, LLC | 4.3% | ||||
|
Prelude Therapeutics Incorporated
13G
PRLD · 74065P101
|
9.9% |
4/28/2026
Event 4/21/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
JATT II Acquisition Corp
13G
JATT · G50765109
|
6.4% |
4/27/2026
Event 4/20/2026
|
|||
| RA Capital Management, L.P. | 6.4% | ||||
| Peter Kolchinsky | 6.4% | ||||
| Rajeev Shah | 6.4% | ||||
| RA Capital Healthcare Fund, L.P. | 6.4% | ||||
|
Acrivon Therapeutics, Inc.
13D/A
Amendment 4
ACRV · 004890109
|
28.8% |
4/23/2026
Event 4/22/2026
|
|||
| RA Capital Management, L.P. | 28.8% | ||||
| Peter Kolchinsky | 28.8% | ||||
| Rajeev Shah | 28.8% | ||||
| RA Capital Healthcare Fund, L.P. | 27.7% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 17
VOR · 929033207
|
19.9% |
4/21/2026
Event 4/20/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Wave Life Sciences Ltd.
13D/A
Amendment 10
WVE · Y95308105
|
17.1% |
4/17/2026
Event 4/15/2026
|
|||
| RA Capital Management, L.P. | 17.1% | ||||
| Peter Kolchinsky | 17.1% | ||||
| Rajeev Shah | 17.1% | ||||
| RA Capital Healthcare Fund, L.P. | 17.1% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 16
VOR · 929033207
|
19.9% |
4/15/2026
Event 4/14/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Adicet Bio, Inc.
13G/A
Amendment 3
ACET · 007002207
|
12.3% |
4/13/2026
Event 2/17/2026
|
|||
| RA Capital Management, L.P. | 12.3% | ||||
| Peter Kolchinsky | 12.3% | ||||
| Rajeev Shah | 12.3% | ||||
| RA Capital Healthcare Fund, L.P. | 12.3% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 15
VOR · 929033207
|
19.9% |
4/10/2026
Event 4/9/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 14
VOR · 929033207
|
19.9% |
4/8/2026
Event 4/6/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Aclaris Therapeutics, Inc.
13G
ACRS · 00461U105
|
6.3% |
4/7/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 6.3% | ||||
| Peter Kolchinsky | 6.3% | ||||
| Rajeev Shah | 6.3% | ||||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||||
|
OnKure Therapeutics, Inc.
13G
OKUR · 68277Q105
|
9.9% |
4/7/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Zai Lab Limited
13G
ZLAB · 98887Q104
|
5.2% |
4/6/2026
Event 3/30/2026
|
|||
| RA Capital Management, L.P. | 5.2% | ||||
| Peter Kolchinsky | 5.2% | ||||
| Rajeev Shah | 5.2% | ||||
| RA Capital Healthcare Fund, L.P. | 5.2% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U205
|
9.9% |
4/2/2026
Event 3/26/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 13
VOR · 929033207
|
19.9% |
4/1/2026
Event 3/30/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Xencor, Inc.
13G
XNCR · 98401F105
|
6.5% |
3/30/2026
Event 3/23/2026
|
|||
| RA Capital Management, L.P. | 6.5% | ||||
| Peter Kolchinsky | 6.5% | ||||
| Rajeev Shah | 6.5% | ||||
| RA Capital Healthcare Fund, L.P. | 6.5% | ||||
|
Wave Life Sciences Ltd.
13D/A
Amendment 9
WVE · Y95308105
|
17.5% |
3/30/2026
Event 3/26/2026
|
|||
| RA Capital Management, L.P. | 17.5% | ||||
| Peter Kolchinsky | 17.5% | ||||
| Rajeev Shah | 17.5% | ||||
| RA Capital Healthcare Fund, L.P. | 17.4% | ||||
|
Acrivon Therapeutics, Inc.
13D/A
Amendment 3
ACRV · 004890109
|
21.6% |
3/23/2026
Event 3/19/2026
|
|||
| RA Capital Management, L.P. | 21.6% | ||||
| Peter Kolchinsky | 21.6% | ||||
| Rajeev Shah | 21.6% | ||||
| RA Capital Healthcare Fund, L.P. | 20.4% | ||||
|
SAB Biotherapeutics, Inc.
13D/A
Amendment 2
SABS · 78397T202
|
9.9% |
3/23/2026
Event 3/19/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Equillium, Inc.
13G
EQ · 29446K106
|
9.9% |
3/20/2026
Event 3/13/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 12
SLDB · 83422E204
|
9.9% |
3/17/2026
Event 3/13/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||||
|
Acumen Pharmaceuticals, Inc.
13D/A
Amendment 4
ABOS · 00509G209
|
29.5% |
3/17/2026
Event 3/13/2026
|
|||
| RA Capital Management, L.P. | 29.5% | ||||
| Peter Kolchinsky | 29.5% | ||||
| Rajeev Shah | 29.5% | ||||
| RA Capital Healthcare Fund, L.P. | 26.8% | ||||
|
Vor Biopharma Inc.
13D/A
Amendment 12
VOR · 929033207
|
19.9% |
3/16/2026
Event 3/12/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
SAB Biotherapeutics, Inc.
13D/A
Amendment 1
SABS · 78397T202
|
9.9% |
3/11/2026
Event 3/9/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 11
SLDB · 83422E204
|
9.9% |
3/10/2026
Event 3/6/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||||
|
Tyra Biosciences, Inc.
13D/A
Amendment 6
TYRA · 90240B106
|
21.2% |
3/6/2026
Event 3/4/2026
|
|||
| RA Capital Management, L.P. | 21.2% | ||||
| Peter Kolchinsky | 21.2% | ||||
| Rajeev Shah | 21.2% | ||||
| RA Capital Healthcare Fund, L.P. | 17.7% | ||||
|
Bicara Therapeutics Inc.
13D/A
Amendment 1
BCAX · 055477103
|
11.5% |
3/2/2026
Event 2/26/2026
|
|||
| RA Capital Management, L.P. | 11.5% | ||||
| Peter Kolchinsky | 11.5% | ||||
| Rajeev Shah | 11.5% | ||||
| RA Capital Healthcare Fund, L.P. | 7.3% | ||||
|
Evommune, Inc.
13D/A
Amendment 1
EVMN · 30054Y107
|
9.7% |
2/17/2026
Event 2/12/2026
|
|||
| RA Capital Management, L.P. | 9.7% | ||||
| Peter Kolchinsky | 9.7% | ||||
| Rajeev Shah | 9.7% | ||||
| RA Capital Healthcare Fund, L.P. | 7.5% | ||||
|
Spyglass Pharma, Inc.
13D
SGP · 85220G109
|
24.1% |
2/17/2026
Event 2/9/2026
|
|||
| RA Capital Management, L.P. | 24.1% | ||||
| Peter Kolchinsky | 24.1% | ||||
| Rajeev Shah | 24.1% | ||||
| RA Capital Healthcare Fund, L.P. | 17.9% | ||||
| RA Capital Nexus Fund III, L.P. | 6.2% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 6
UNCY · 90466Y202
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Surrozen, Inc.
13G/A
Amendment 2
SRZN · 86889P208
|
9.2% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.2% | ||||
| Peter Kolchinsky | 9.2% | ||||
| Rajeev Shah | 9.2% | ||||
| RA Capital Healthcare Fund, L.P. | 9.2% | ||||
|
Rhythm Pharmaceuticals, Inc.
13G/A
Amendment 8
RYTM · 76243J105
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 1
PALI · 696389402
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Monopar Therapeutics Inc.
13G/A
Amendment 3
MNPR · 61023L207
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
LB Pharmaceuticals Inc
13G/A
Amendment 1
LBRX · 50180M108
|
8.7% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 8.7% | ||||
| Peter Kolchinsky | 8.7% | ||||
| Rajeev Shah | 8.7% | ||||
| RA Capital Healthcare Fund, L.P. | 8.7% | ||||
|
Larimar Therapeutics, Inc.
13G/A
Amendment 1
LRMR · 517125100
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Invivyd, Inc.
13G/A
Amendment 1
IVVD · 00534A102
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Fulcrum Therapeutics, Inc.
13G/A
Amendment 6
FULC · 359616109
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Eledon Pharmaceuticals, Inc.
13G/A
Amendment 1
ELDN · 28617K101
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||